p53-independent mechanisms regulate the P2-MDM2 promoter in adult astrocytic tumours

• Published in: British journal of cancer 2008-10, Vol.99 (7), p.1144-1152
• Main Authors: Dimitriadi, M, Poulogiannis, G, Liu, L, Bäcklund, L M, Pearson, D M, Ichimura, K, Collins, V P
• Format: Article
• Language: English
• Subjects: Adult; Biological and medical sciences; Biomedical and Life Sciences; Biomedicine; Brain Neoplasms - genetics; Cancer Research; Cell cycle; Drug Resistance; Epidemiology; Genotype; Glioblastoma - genetics; Humans; Kinases; Medical research; Medical sciences; Medicin och hälsovetenskap; Molecular Diagnostics; Molecular Medicine; Neurology; Oncology; Polymorphism; Promoter Regions, Genetic; Proteins; Proto-Oncogene Proteins c-mdm2 - genetics; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger - genetics; Transcription factors; Tumor Suppressor Protein p53 - physiology; Tumors; Tumors of the nervous system. Phacomatoses
• ISSN: 0007-0920; 1532-1827; 1532-1827
• DOI: 10.1038/sj.bjc.6604643

The MDM2 gene is amplified and/or overexpressed in about 10% of glioblastomas and constitutes one of a number of ways the p53 pathway is disrupted in these tumours. MDM2 encodes a nuclear phosphoprotein that regulates several cell proteins by binding and/or ubiquitinating them, with p53 being a well-established partner. MDM2 has two promoters, P1 and P2 that give rise to transcripts with distinct 5′ untranslated regions. Transcription from P2 is believed to be controlled by p53 and a single-nucleotide polymorphism (SNP309, T>G) in P2 is reported to be associated with increased risk for, and early development of, malignancies. The use of P1 and P2 has not been investigated in gliomas. We used RT–PCR to study P1- and P2-MDM2 transcript expression in astrocytic tumours, xenografts and cell lines with known MDM2 , TP53 and p14 ARF gene status. Both promoters were used in all genetic backgrounds including the use of the P2 promoter in TP53 null cells, indicating a p53-independent induction of transcription. Transcripts from the P1 promoter formed a greater proportion of the total MDM2 transcripts in tumours with MDM 2 amplification, despite these tumours having two wild-type TP53 alleles. Examination of SNP309 in glioblastoma patients showed a borderline association with survival but no apparent correlation with age at diagnosis nor with TP53 and p14 ARF status of their tumours. Our findings also indicate that elevated MDM2 mRNA levels in tumours with MDM2 amplification are preferentially driven by the P1 promoter and that the P2 promoter is not only regulated by p53 but also by other transcription factor(s).